Keyphrases
Japanese children
100%
Older Adults
100%
Respiratory Syncytial Virus
100%
Outpatient Cost
100%
Inpatient Costs
100%
Palivizumab
27%
Respiratory Syncytial Virus Infection
27%
Medical Computer Vision
27%
Japan
18%
Risk Factors
18%
Treatment Costs
18%
Claims Database
18%
Hospitalized Older Adults
18%
Virus Diseases
18%
Hospitalised Infants
18%
Mean Cost
18%
Health Care Costs
9%
Hospitalization
9%
Retrospective Analysis
9%
Airway
9%
Medical Management
9%
Virus Detection
9%
Intensive Care Unit
9%
High Cost
9%
Healthcare Resource Utilization
9%
Palivizumab Prophylaxis
9%
Plain Language Summary
9%
Hospital Care
9%
Economic Burden
9%
Health Care Use
9%
Insurance Database
9%
Intensive Care Unit Stay
9%
Cumulative Costs
9%
Adult Cohort
9%
Medicine Use
9%
Nursing and Health Professions
Outpatient
100%
Palivizumab
100%
Respiratory Syncytial Virus Infection
75%
Intensive Care Unit
50%
Virus Infection
50%
Hospitalized Older Adults
50%
Disease
25%
Disease Management
25%
Health Care Utilization
25%
Health Care Cost
25%
Virus Diagnosis
25%
Hospital Care
25%
Pharmacology, Toxicology and Pharmaceutical Science
Human Respiratory Syncytial Virus
100%
Palivizumab
36%
Disease
27%
Respiratory Syncytial Virus Infection
27%
Immunology and Microbiology
Human Respiratory Syncytial Virus
100%
Palivizumab
36%
Respiratory Syncytial Virus Infection
27%
Biochemistry, Genetics and Molecular Biology
Human Respiratory Syncytial Virus
100%
Palivizumab
28%